Prostate cancer is entering the era of 'precision medicine', bringing a new approach and a new class of highly-focused drugs that have begun helping men with a particular genetic defect.
The DDR genetic defect occurs in 10-12 per cent of men with lethal prostate cancer. Westend61
A new form of treatment is emerging for prostate cancer. Rather than the traditional “one-size fits all” approach developed for the average man; this new approach is tailored to the individual man.
Using sophisticated technology and smart drugs, it targets the particular genetic make-up of his prostate tumour.
Fetching latest articles
Original URL: https://www.afr.com/link/follow-20180101-p53pcu
